Net revenues increased by 11.6% to $297.2 million in 2025, up from $266.3 million in 2024, primarily due to the U.S. launch of Evolysse and increased Jeuveau sales. The company reported a net loss of $51.6 million for the year ended December 31, 2025, compared to a net loss of $50.4 million in 2024. Gross profit margin decreased to 66.3% in 2025 from 68.5% in 2024, influenced by product and geographic mix, and promotional programs. Selling, general and administrative expenses rose by 11.5% to $220.8 million in 2025, mainly due to higher personnel costs for commercial activities and Evolysse launch training. Research and development expenses increased slightly to $9.6 million in 2025, driven by increased clinical operations. Evolus launched Evolysse Form and Evolysse Smooth injectable HA gels in the United States in April 2025, indicated for wrinkles and folds. The company secured a new $30.0 million asset-based revolving credit facility in March 2026 and amended its term loan agreement with Pharmakon in May 2025, providing up to $250.0 million in senior secured term loans. Cash used in operating activities significantly increased to $42.3 million in 2025 from $18.0 million in 2024, largely due to higher operating loss and increased inventory purchases. An accumulated deficit of $661.0 million was reported as of December 31, 2025.